ReviewPharmacological reports : PR2026

Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.

Piotr Ryszkiewicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.